Navigation Links
Hepatitis C Therapeutics Market - Taiwan
Date:8/2/2010

NEW YORK, Aug. 2 /PRNewswire/ --Reportlinker.com announces that a new market research report is available in its catalogue:

Hepatitis C Therapeutics Market - Taiwan

http://www.reportlinker.com/p0236386/Hepatitis-C-Therapeutics-Market---Taiwan.html

This research service aims to provide an update on the epidemiology of Hepatitis C, including the prevalence and incidence, Market Engineering measurements, and government initiatives. It also covers patient source, load, and forecasts, while also outlining the key treaters involved. Current diagnostic methods are presented, followed by treatment regimens, their cost, and upcoming product launches. Clinical trials highlighting research into new treatments are also provided, along with an analysis of the pipeline. Additionally, there is a competitive analysis which includes the market structure, major participants, and future trends. This service covers the Hepatitis C therapeutics market in Taiwan. 

1 EXECUTIVE SUMMARY

Overview

1. Executive Summary - Taiwan

2 HEPATITIS C THERAPEUTICS MARKET

Market Overview

1. Introduction

2. Context for the Study

3. Report Scope and Segmentation

4. Methodology

5. Restraints in Forecasts

3 TAIWAN HEPATITIS C THERAPEUTICS MARKET

Market Overview

1. Introduction

2. Measurements

3. Government Initiatives

Hepatitis C Patients

1. Patient Load

2. Key Treaters and Patient Flow

3. Patient Forecasts

Diagnosis and Treatment

1. Diagnostic Tests and Monitoring

2. Treatment Regimens

3. Cost of Treatment

4. Product Launches

5. Clinical Trials

Competitive Analysis

1. Competitive Structure

2. Future Trends

3. Challenges Faced by Physicians

4 APPENDIX

Taiwan

1. Appendix-1

List of Figures

Chapter 3

Hepatitis C Therapeutics Market: Prevalence of Hepatitis C (Taiwan), 2006-2016 Hepatitis C Therapeutics Market: Incidence of Hepatitis C (Taiwan), 2006-2016

Hepatitis C Therapeutics Market: Classification of Patients who have Previously Received Interferon-based Therapy (Taiwan), 2009

Hepatitis C Therapeutics Market: Patient Classification of Current HCV Patients Based on Genotype (Taiwan), 2009

Hepatitis C Therapeutics Market: Number of Diagnosed Hepatitis C Patients (Taiwan), 2006-2016

Hepatitis C Therapeutics Market: Market Drivers Ranked in Order of Impact for Treated Chronic Hepatitis C Patient (Taiwan), 2010-2016

Hepatitis C Therapeutics Market: Market Restraints Ranked in Order of Impact for Treated Chronic Hepatitis C Patient (Taiwan), 2010-2016

Hepatitis C Therapeutics Market: Treated and Under Observation Chronic Hepatitis C Patients Forecasts (Taiwan), 2006-2016

Hepatitis C Therapeutics Market: Treated Chronic Hepatitis C Patients Forecasts (Taiwan), 2006-2016

Hepatitis C Therapeutics Market: Circumstances that Prompt Physicians to Test Patients for HCV (Taiwan), 2009

Hepatitis C Therapeutics Market: Key Diagnostic Tests Prior to Hepatitis C Treatment Therapy (Taiwan), 2009

Hepatitis C Therapeutics Market: Diagnostic Tests and Key Clinical Indicators (Taiwan), 2009

Hepatitis C Therapeutics Market: Treatment Regimen for Genotype 1 Chronic HCV Patients (Taiwan), 2009

Hepatitis C Therapeutics Market: Treatment Regimen for Genotype 2 and 3 Chronic HCV Patients (Taiwan), 2009

Hepatitis C Therapeutics Market: Treatment Regimen for Naive Chronic HCV Patients (Taiwan), 2009

Hepatitis C Therapeutics Market: Advantages and Drawbacks of Prescribed Drugs (Taiwan), 2009

Hepatitis C Therapeutics Market: Cost of Therapy (Listed Price) per Patient for Various Drug Regimens for the Treatment of Hepatitis C (Taiwan), 2009 3-29

Hepatitis C Therapeutics Market Product Launches (Taiwan), 2011 and 2013

Hepatitis C Therapeutics Market: List of Clinical Trials Conducted by Phase, Patient Age, Stage, Drug and Sponsor (Taiwan), 2009

Hepatitis C Therapeutics Market: List of Interferons in Development (World), 2009

Hepatitis C Therapeutics Market: List of Small Molecule Antivirals in Development (World), 2009

Hepatitis C Therapeutics Market: List of Non-Interferons in Development (World), 2009

Hepatitis C Therapeutics Market: Competitive Structure (Taiwan), 2009

To order this report:

Drug and Medication Industry: Hepatitis C Therapeutics Market - Taiwan

More  Market Research Report

Check our  Company Profile, SWOT and Revenue Analysis!

Nicolas Bombourg

Reportlinker

Email: nbo@reportlinker.com

US: (805)652-2626

Intl: +1 805-652-2626


'/>"/>
SOURCE Reportlinker
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. Romark Initiates Clinical Trial of Alinia(R) for Chronic Hepatitis C in the United States
2. Drug in New Hepatitis C Clinical Trial
3. Anadys Pharmaceuticals Presents Preclinical Results on ANA598, a Non-Nucleoside Inhibitor of the NS5B Polymerase, at the 14th International Symposium on Hepatitis C Virus and Related Viruses
4. CEL-SCI Presents Data for CEL-1000 as a Vaccine Adjuvant with Recombinant Hepatitis B Virus Protein
5. Dynavaxs HEPLISAV(TM) Hepatitis B Vaccine Maintains Full Immunogenicity at 50 Weeks in Phase 3 Trial
6. European Unions CHMP Issues Positive Opinion on PEGINTRON(TM) Combination Therapy for Retreating Hepatitis C Patients Who Failed Previous Therapy
7. Pharmasset Commences Dosing in 28-Day Combination Study of R7128 with Pegasys(R) plus Copegus(R) for Hepatitis C
8. Initial Results of Phase II Study with HCV Protease Inhibitor Boceprevir in Treatment-Naive Hepatitis C Patients Show a High Rate of Early Virologic Response
9. R7128 Receives Fast Track Designation from the FDA for the Treatment of Chronic Hepatitis C Infection
10. Potent Hepatitis C Virus Inhibitors Show Efficacy and Potential for Once Daily Dosing in Preclinical Studies
11. Roches Investigational Polymerase Inhibitor, Combined with PEGASYS(R) and COPEGUS(TM), Shows Potent Antiviral Activity in Treatment of Chronic Hepatitis C at Four Weeks
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/19/2017)... 19, 2017  Novartis today announced the publication ... Lung, and Blood Institute (NHLBI) of the National ... patients with treatment-naïve severe aplastic anemia (SAA) achieved ... eltrombopag at the initiation of and concurrently with ... three sequential treatment groups, or cohorts. Cohort 3 ...
(Date:4/18/2017)... MINNEAPOLIS , April 18, 2017 Cogentix ... focused on providing the Urology, Uro/Gyn and Gynecology markets ... for the first quarter ended March 31, 2017 after ... The Company will host a conference call ... day on Tuesday, May 2, 2017 at 4:30 p.m. ...
(Date:4/18/2017)... , April 18, 2017  Astute Medical, Inc., developer ... series to be presented at the 2017 National Kidney ... today and continues through April 22. Physicians will present ... used to assess risk for acute kidney injury (AKI) ... failure (ADHF). Elevated levels of TIMP-2 ...
Breaking Medicine Technology:
(Date:4/29/2017)... (PRWEB) , ... April 29, 2017 , ... Phytomer USA ... As a Phytomer Account Manager, Smith’s role is to provide excellent customer ... that make up The Phytomer Group. Smith comes to Phytomer with a wealth of ...
(Date:4/28/2017)... ... April 28, 2017 , ... The National Campaign to ... the Access to Contraception for Women Servicemembers and Dependents Act of 2017. The ... will help to ensure that all members of the Armed Forces receive high ...
(Date:4/28/2017)... ... April 28, 2017 , ... Horizon Blue Cross Blue Shield of New Jersey ... “A” and its outlook as “stable.” At the same time, the ratings agency cautioned ... recent years, dip below “capital adequacy” thresholds required for its strong rating. , “Horizon ...
(Date:4/28/2017)... ... April 28, 2017 , ... The Radiology Business Management ... officers for 2017-2018. The annual board election process has been in place since the ... , Thomas C. Dickerson, Ed.D., FACHE, succeeds Jim Hamilton, MHA, CMM, FRBMA, as president. ...
(Date:4/28/2017)... ... April 28, 2017 , ... ... liability could substantially improve drug safety and minimize the cost of development. In ... ion channel inhibition using cell lines and for cardiac toxicity using induced pluripotent ...
Breaking Medicine News(10 mins):